Alopexx, акция обыкновенная (ALPX)

Alopexx, Inc. operates as a clinical stage biotechnology company. The Company develops novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). Alopexx serves customers worldwide.

• Чистая прибыль
• EBITDA
• Активы
• Капитал
• Чистый долг / EBITDA
• Общий долг / Капитал